A randomized, investigator-masked clinical trial comparing the efficacy and safety of gatifloxacin 0.3% administered BID versus QID for the treatment of acute bacterial conjunctivitis

Current Medical Research and Opinion

Volumn 21, Issue 3, 2005, Pages 425-431

  Yee, Richard W ^a   Tepedino, Michael ^b   Bernstein, Paula ^c   Jensen, Harold ^c   Schiffman, Rhett ^c   Whitcup, Scott M ^c  

^a Hermann Eye Center   (United States)

^b Pediatric Nurse Practitioner   (United States)

^c ALLERGAN INC   (United States)

Author keywords

Bacterial conjunctivitis; Fluoroquinolones; Gatifloxacin

Indexed keywords

EYE DROPS; GATIFLOXACIN;

ADULT; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL INFECTION; BACTERIUM CULTURE; BACTERIUM ISOLATE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DILUTION; DRUG EFFECT; DRUG POTENCY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; PARALLEL DESIGN; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; SYMPTOM; TREATMENT OUTCOME;

ACUTE DISEASE; ADMINISTRATION, ORAL; ADULT; CONJUNCTIVITIS, BACTERIAL; FEMALE; FLUOROQUINOLONES; HUMANS; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 16844371197     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079905X30699     Document Type: Article

References (13)

1. Mah FS. Fourth-generation fluoroquinolones: new topical agents in the war on ocular bacterial infections. Curr Opin Ophthalmol 2004;15:316-20
2. Mather R, Karenchak LM, Romanowski EG, Kowalski RP. Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics. Am J Ophthalmol 2002;133:463-6
3. Monica ML, Jensen HG. Ocular bacteria from conjunctivitis patients: susceptibility to gatifloxacin and older fluoroquinolones. Presented at: Annual Meeting of the Association for Research in Vision and Ophthalmology; May 4-9, 2003; Ft. Lauderdale, FL
4. Tepedino ME, Jensen HE. Efficacy and safety of gatifloxacin 0.3% ophthalmic solution compared with ofloxacin 0.3% for treatment of acute bacterial conjunctivitis. Poster presented at: Annual Meeting of the American Academy of Ophthalmology (AAO); October 20-23, 2002; Orlando, FL
5. Sheikh A, Hurwitz B. Topical antibiotics for acute bacterial conjunctivitis: a systematic review. Br J Gen Pract 2001;51:473-7
6. Sheikh A, Hurwitz B, Cave J. Antibiotics for acute bacterial conjunctivitis. Cochrane Database Syst Rev 2000;CD001211
7. Martin M, Turco JH, Zegans ME, et al. An outbreak of conjunctivitis due to atypical Streptococcus pneumoniae. New Engl J Med 2003;348(12):1112-21
8. Leibowitz HM. Antibacterial effectiveness of ciprofloxacin 0.3% ophthalmic solution in the treatment of bacterial conjunctivitis. Am J Ophthalmol 1991;112(Suppl 4):29S-33S
9. Miller IM, Wittreich J, Vogel R, Cook TJ. The safety and efficacy of topical norfloxacin compared with placebo in the treatment of acute, bacterial conjunctivitis. [The Norfloxacin-Placebo Ocular Study Group]. Eur J Ophthalmol 1992;2:58-66
10. Chrai SS, Makoid MC, Eriksen SP, Robinson JR. Drop size and initial dosing frequency problems of topically applied ophthalmic drugs. J Pharm Sci 1974;63:333-8
11. Friedlaender MH. Twice-a-day versus four-times-a-day ofloxacin treatment of external ocular infection. CLAO J 1998;24:48-51
12. Ting, N. Carry-forward analysis. In: Chow S, editor. Encyclopedia of biopharmaceutical statistics. New York: Marcel Dekker; 2001;103-4
13. Schwab IR, Friedlaender M, McCulley J, Lichtenstein SJ, Moran CT; Levofloxacin Bacterial Conjunctivitis Active Control Study Group. A phase III clinical trial of 0.5% levofloxacin ophthalmic solution versus 0.3% ofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis. Ophthalmology 2003;110:457-65